Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Applied DNA Sciences Inc APDN

Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic... see more

NDAQ:APDN - Post Discussion

Applied DNA Sciences Inc > APDN Having Serious Cash Problems!!! (See Latest SEC Filing)
View:
Post by turner20001 on Jan 06, 2024 9:39pm

APDN Having Serious Cash Problems!!! (See Latest SEC Filing)

"On January 4, 2024, in connection with certain cost management efforts, Applied DNA Sciences, Inc. (the "Company”) entered into letter agreements with the Company’s President and Chief Executive Officer, James A. Hayward, Ph.D., Sc.D. (the "Hayward Letter Agreement”), and the Company’s Chief Operating Officer, Judith Murrah (the "Murrah Letter Agreement”). The Hayward Letter Agreement amends Dr. Hayward’s employment agreement with the Company and provides for a temporary 45% reduction to Dr. Hayward’s annual base salary, from $450,000 to $250,000, for a period of three months, effective as of January 1, 2024 through March 31, 2024. Dr. Hayward also agreed to waive any right to resign for "good reason” under his employment agreement with the Company as a result of the foregoing salary reduction. The Murrah Letter Agreement provides for a temporary 25% reduction to Ms. Murrah’s annual base salary, from $325,000 to $243,750, for a period of three months, effective as of January 1, 2024 through March 31, 2024."
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities